Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
about
Proteomic Analysis of Anticancer TCMs Targeted at MitochondriaClinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Cytoplasmic HSP90α expression is associated with perineural invasion in pancreatic cancer.RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement.Examination of Gossypol-Pluronic Micelles as Potential Radiosensitizers.
P2860
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@en
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@nl
type
label
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@en
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@nl
prefLabel
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@en
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@nl
P2093
P2860
P1433
P1476
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
@en
P2093
Andrei Laszlo
Dennis E Hallahan
Dinesh Thotala
P2860
P304
P356
10.1097/PPO.0B013E31829A68EB
P577
2013-05-01T00:00:00Z